ARCHIVES

Genentech Reps Not Welcome: Hospitals Urge Drug Maker to Reverse Policy On Supplying Avastin, Rituxan, & Herceptin

This article is from The Cancer Letter archive.

Vol. 40 No. 39 | October 17, 2014

Download PDF Visit The Full Archive

Related Articles

Genasense Added To Chemo Improves Responses in CLL

December 31, 2004

CCOPS Unhappy With NCI Policy Limiting Their Participation In Early Phase 2 Clinical Trials

November 11, 1983

Tamoxifen: No Mortality Benefit For Most “High Risk” Women

September 29, 2006

Public Forum On NRSA Tuition Policies

April 14, 1995

Research Suggestions Considered By DCBD Diagnostic Group

July 11, 1980

Horvitz Wins BMS Award In Neuroscience; Group Room To Discuss Congressional Issues.

February 22, 2002